BR112018009032A8 - vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração - Google Patents

vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração

Info

Publication number
BR112018009032A8
BR112018009032A8 BR112018009032A BR112018009032A BR112018009032A8 BR 112018009032 A8 BR112018009032 A8 BR 112018009032A8 BR 112018009032 A BR112018009032 A BR 112018009032A BR 112018009032 A BR112018009032 A BR 112018009032A BR 112018009032 A8 BR112018009032 A8 BR 112018009032A8
Authority
BR
Brazil
Prior art keywords
viral vector
infectious arenavirus
arenavirus viral
treating
vaccine
Prior art date
Application number
BR112018009032A
Other languages
English (en)
Other versions
BR112018009032A2 (pt
Inventor
Cohen Katherine
Monath Thomas
Baumgartlstrasser Vera
Original Assignee
Hookipa Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech Ag filed Critical Hookipa Biotech Ag
Publication of BR112018009032A2 publication Critical patent/BR112018009032A2/pt
Publication of BR112018009032A8 publication Critical patent/BR112018009032A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção refere-se a imunoterapias para infecções pelo vírus da hepatite b. o presente pedido de patente provê vetores arenavirais geneticamente modificados, adequados como vacinas para a prevenção e o tratamento de infecções pelo vírus da hepatite b. além disso, são providas também composições farmacêuticas e métodos para o tratamento de infecções pelo vírus da hepatite b. especificamente, são providas no presente composições farmacêuticas, vacinas e métodos para tratar infecção pelo vírus da hepatite b.
BR112018009032A 2015-11-04 2016-11-03 vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração BR112018009032A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250639P 2015-11-04 2015-11-04
PCT/EP2016/076591 WO2017076988A1 (en) 2015-11-04 2016-11-03 Vaccines against hepatitis b virus

Publications (2)

Publication Number Publication Date
BR112018009032A2 BR112018009032A2 (pt) 2018-11-06
BR112018009032A8 true BR112018009032A8 (pt) 2019-02-26

Family

ID=57249796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018009032A BR112018009032A8 (pt) 2015-11-04 2016-11-03 vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração

Country Status (22)

Country Link
US (2) US11214598B2 (pt)
EP (2) EP3371316B1 (pt)
JP (3) JP6914950B2 (pt)
KR (1) KR20180082485A (pt)
CN (2) CN115948467A (pt)
AU (2) AU2016348675B2 (pt)
BR (1) BR112018009032A8 (pt)
CA (1) CA3003557A1 (pt)
DK (1) DK3371316T3 (pt)
ES (1) ES2934698T3 (pt)
FI (1) FI3371316T3 (pt)
HK (1) HK1255847A1 (pt)
HR (1) HRP20221474T1 (pt)
HU (1) HUE060648T2 (pt)
IL (1) IL259077A (pt)
LT (1) LT3371316T (pt)
MX (2) MX2018005569A (pt)
PL (1) PL3371316T3 (pt)
PT (1) PT3371316T (pt)
SG (1) SG11201803474UA (pt)
SI (1) SI3371316T1 (pt)
WO (1) WO2017076988A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5642556B2 (ja) 2007-12-27 2014-12-17 ユニヴァーシテト チューリッヒ 複製欠損アレナウイルスベクター
US10111945B2 (en) 2013-12-03 2018-10-30 Hookipa Biotech Gmbh CMV vaccines
CA2967720C (en) * 2014-11-13 2024-01-02 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
EP3371316B1 (en) 2015-11-04 2022-10-19 Hookipa Biotech GmbH Vaccines against hepatitis b virus
LT3373959T (lt) 2015-11-12 2022-07-25 Hookipa Biotech Gmbh Arenavirusų dalelės, kaip vėžio vakcinos
EP3526323B1 (en) 2016-10-14 2023-03-29 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
JP2022010188A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
JP2022010187A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
CN114630675A (zh) * 2019-06-18 2022-06-14 爱尔兰詹森科学公司 乙型肝炎病毒(hbv)疫苗和抗pd-1或抗pd-l1抗体的组合
MA56524A (fr) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Co Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
AU2020357502A1 (en) 2019-09-30 2022-05-19 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
EP4069729A1 (en) 2019-12-06 2022-10-12 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
KR20220131918A (ko) 2019-12-24 2022-09-29 카나 바이오사이언스, 인코포레이션 다이아실글리세롤 키나제 조절 화합물
EP4121437A1 (en) 2020-03-20 2023-01-25 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
KR102375703B1 (ko) 2020-07-28 2022-03-17 경북대학교 산학협력단 사물 인터넷 환경에서 CoAP 기반의 데이터 스트리밍 방법 및 통신 시스템
CN117280027A (zh) 2021-03-23 2023-12-22 霍欧奇帕生物科技有限公司 用于治疗前列腺癌的沙粒病毒
WO2022226242A1 (en) * 2021-04-21 2022-10-27 La Jolla Institute For Immunology Engineered arenavirus glycoprotein compositions, methods and use thereof
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用
AU2022274607A1 (en) 2021-05-13 2023-11-16 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
AU2022299051A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH1084967A (ja) 1996-09-19 1998-04-07 Fujirebio Inc Ｂ型肝炎のｅ抗原
CA2352738A1 (en) * 1998-12-04 2000-06-08 Biogen, Inc. Hbv core antigen particles with multiple immunogenic components attached via peptide ligands
FR2803599B1 (fr) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
EP1888622A1 (en) * 2005-05-23 2008-02-20 Oxxon Therapeutics Ltd. Compositions for inducing an immune response against hepatitis b
WO2007109812A2 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CA2947292C (en) * 2006-12-27 2019-07-23 Emory University Compositions and methods for the treatment of infections and tumors
JP5642556B2 (ja) 2007-12-27 2014-12-17 ユニヴァーシテト チューリッヒ 複製欠損アレナウイルスベクター
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
TWI555531B (zh) 2009-08-07 2016-11-01 傳斯堅公司 用以治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
CN110042110A (zh) 2012-01-24 2019-07-23 桑福德健康公司 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸
ES2751423T3 (es) 2013-03-15 2020-03-31 Univ Geneve Vacunas antimicobacterianas
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
US10111945B2 (en) 2013-12-03 2018-10-30 Hookipa Biotech Gmbh CMV vaccines
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
EP3198008B1 (en) 2014-09-22 2019-05-29 Regents of the University of Minnesota Pichinde virus reverse genetics system and methods of use
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
CA2967720C (en) 2014-11-13 2024-01-02 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
EP3365005A1 (en) 2015-10-23 2018-08-29 Institut Pasteur Recombinant mopeia virus and vaccine platform
EP3371316B1 (en) 2015-11-04 2022-10-19 Hookipa Biotech GmbH Vaccines against hepatitis b virus
LT3373959T (lt) 2015-11-12 2022-07-25 Hookipa Biotech Gmbh Arenavirusų dalelės, kaip vėžio vakcinos
WO2017190074A1 (en) 2016-04-28 2017-11-02 The University Of Chicago Lymphangiogenesis for therapeutic immunomodulation
AU2017266738B2 (en) 2016-05-18 2023-10-12 Hookipa Biotech Gmbh Tri-segmented Pichinde viruses as vaccine vectors
US20200206334A1 (en) 2016-11-04 2020-07-02 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
CN110719788A (zh) 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒

Also Published As

Publication number Publication date
EP4177348A1 (en) 2023-05-10
AU2023200108A1 (en) 2023-02-16
JP2024010027A (ja) 2024-01-23
MX2023013140A (es) 2023-11-28
CN115948467A (zh) 2023-04-11
HK1255847A1 (zh) 2019-08-30
NZ741950A (en) 2023-10-27
JP2021182922A (ja) 2021-12-02
HRP20221474T1 (hr) 2023-01-06
SG11201803474UA (en) 2018-05-30
CA3003557A1 (en) 2017-05-11
PT3371316T (pt) 2022-11-17
IL259077A (en) 2018-06-28
AU2016348675B2 (en) 2022-11-17
AU2016348675A1 (en) 2018-05-17
PL3371316T3 (pl) 2023-02-13
US20220073568A1 (en) 2022-03-10
HUE060648T2 (hu) 2023-04-28
WO2017076988A1 (en) 2017-05-11
BR112018009032A2 (pt) 2018-11-06
MX2018005569A (es) 2018-12-19
SI3371316T1 (sl) 2023-02-28
EP3371316A1 (en) 2018-09-12
KR20180082485A (ko) 2018-07-18
ES2934698T3 (es) 2023-02-24
CN108779472A (zh) 2018-11-09
US11214598B2 (en) 2022-01-04
JP6914950B2 (ja) 2021-08-11
US20180319845A1 (en) 2018-11-08
DK3371316T3 (da) 2023-01-23
JP2018536433A (ja) 2018-12-13
FI3371316T3 (fi) 2023-01-13
LT3371316T (lt) 2022-11-25
EP3371316B1 (en) 2022-10-19
CN108779472B (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
BR112018009032A8 (pt) vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração
CY1124288T1 (el) Cmv εμβολια
PH12018500571A1 (en) Hepatitis b core protein modulators
EP4233898A3 (en) Influenza mrna vaccines
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
MX2018014573A (es) Vacuna contra el virus del zika.
EA201890999A1 (ru) Вакцина против вируса простого герпеса
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CY1121874T1 (el) Παραγωγα μονο- ή διυποκατεστημενου ινδολιου ως αναστολεις του αναδιπλασιασμου του ιου του δαγκειου πυρετου
BR112016028816A8 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório
BR112016026721A2 (pt) vacinas com base em vesículas do tipo vírus (vlvs) para prevenir ou tratar infecção por vírus da hepatite b (hbv) crônica
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
EA201391515A1 (ru) Инактивированная вакцина вируса денге
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
BR112015006763B1 (pt) Constructo de ácido nucleico, vetor de transferência plasmídico, partículas de vírus mv-chik, composições, uso da composição, uso das partículas de vírus mv-chik e processo para resgatar vírus do sarampo (mv) recombinante
EA201790160A1 (ru) Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d
BR112015017966A2 (pt) composições imunogênicas compreendendo vírus silificado e métodos de uso
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
MX2019004029A (es) Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
BR112014015582A2 (pt) compostos antivirais
MX2020006476A (es) Vacuna contra el virus de lassa.
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: HOOPIKA RESEARCH GMBH (AT)

B25D Requested change of name of applicant approved

Owner name: HOOKIPA BIOTECH GMBH (AT)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024003112-4 PROTOCOLO 870240013253 EM 16/02/2024 19:09.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]